<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2018-14-4-524-528</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-1721</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>Antithrombotic Therapy after Bleeding in Elderly Polimorbid Patient: Our Time Challenge</article-title><trans-title-group xml:lang="ru"><trans-title>Антитромботическая терапия у пожилого полиморбидного пациента после кровотечения: вызов нашего времени</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Атабегашвили</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Atabegashvili</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Атабегашвили Мария Рубеновна – врач, кардиологическое отделение</p><p>119049, Москва, Ленинскии просп., 10</p></bio><bio xml:lang="en"><p>Maria R. Atabegashvili – MD, Doctor, Department of Cardiology</p><p>Leninsky Prospect 8, Moscow, 119049 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиляров</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyarov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиляров Михаил Юрьевич – доктор медицинских наук, зам. главного врача по терапии, ГКБ №1 им. Н.И. Пирогова; профессор, кафедра профилактической и неотложной кардиологии, Сеченовский Университет</p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>Mikhail Yu. Gilyarov – MD, PhD, Deputy Chief Physician for Therapeutic Care, City Clinical Hospital №1 named after N.I. Pirogov; Professor, Chair of Preventive and Emergency Cardiology, Sechenov University </p><p>Trubetskaya ul. 8-2, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Константинова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Konstantinova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константинова Екатерина Владимировна – доктор медицинских наук, доцент, кафедра факультетской терапии им. акад. А.И. Нестерова, РНИМУ им. Н.И. Пирогова; врач, кардиологическое отделение, ГКБ №1 им. Н.И. Пирогова</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Ekaterina V. Konstantinova – MD, PhD, Associate Professor, Chair of Faculty Therapy named after A.I. Nesterov, Pirogov Russian National Research Medical University; Doctor, Department of Cardiology, City Clinical Hospital №1 named after N.I. Pirogov</p><p>Ostrovitianova ul. 1, Moscow, 117997 </p></bio><email xlink:type="simple">katekons@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костина</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostina</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Костина Анна Николаевна – студентка 6 курса</p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>Anna N. Kostina – 6th Year Student </p><p>Trubetskaya ul. 8-2, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нестеров</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Nesterov</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нестеров Алексей Петрович – кандидат медицинских наук, зав. отделением реанимации и интенсивной терапии для больных инфарктом миокарда </p><p>119049, Москва, Ленинскии просп., 10</p></bio><bio xml:lang="en"><p>Alexey P. Nesterov – MD, PhD, Head of Intensive Care Unit for Patients with Myocardial Infarction </p><p>Leninsky Prospect 8, Moscow, 119049 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пахарькова</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Pakharkova</surname><given-names>T. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пахарькова Татьяна Дмитриевна – студентка 5 курса</p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>Tatyana D. Pakharkova – 5th Year Student </p><p>Trubetskaya ul. 8-2, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Удовиченко</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Udovichenko</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Удовиченко Анна Евгеньевна – кандидат медицинских наук, зав. отделением рентгенхирургических методов диагностики и лечения; доцент</p><p>119991, Москва, ул. Трубецкая, 8 стр. 2</p></bio><bio xml:lang="en"><p>Anna E. Udovichenko – MD, PhD, Head of Department of Interventional Radiology, City ClinicalHospital №1 named after N.I. Pirogov; Associate Professor, Chair of Preventive and Emergency Cardiology, SechenovUniversity</p><p>Trubetskaya ul. 8-2, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городская Клиническая Больница №1 им. Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital №1 named after N.I. Pirogov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская Клиническая Больница №1 им. Н.И. Пирогова; &#13;
Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital №1 named after N.I. Pirogov; &#13;
I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Городская Клиническая Больница №1 им. Н.И. Пирогова; &#13;
Россииский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital №1 named after N.I. Pirogov; &#13;
Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Городская Клиническая Больница №1 им. Н.И. Пирогова; &#13;
Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital №1 named after N.I. Pirogov;&#13;
I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>09</month><year>2018</year></pub-date><volume>14</volume><issue>4</issue><fpage>524</fpage><lpage>528</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Atabegashvili M.R., Gilyarov M.Y., Konstantinova E.V., Kostina A.N., Nesterov A.P., Pakharkova T.D., Udovichenko A.E., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Атабегашвили М.Р., Гиляров М.Ю., Константинова Е.В., Костина А.Н., Нестеров А.П., Пахарькова Т.Д., Удовиченко А.Е.</copyright-holder><copyright-holder xml:lang="en">Atabegashvili M.R., Gilyarov M.Y., Konstantinova E.V., Kostina A.N., Nesterov A.P., Pakharkova T.D., Udovichenko A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/1721">https://www.rpcardio.online/jour/article/view/1721</self-uri><abstract><p>In recent years, there has been a clear trend towards an increase in the number of elderly patients suffering from several polymorbid diseases, which considerably complicates the forecast and tactics of management. A clinical case of an elderly patient, suffering for a long time from type 2 diabetes mellitus, receiving insulin and treated with programmed hemodialysis due to terminal chronic renal failure, and suffering from atrial fibrillation in permanent form, is presented. The patient was hospitalized in theCityClinicalHospital№1 named after N.I. Pirogov due to acute repeated myocardial infarction. An emergency percutaneous coronary intervention was performed, the infarct-dependent artery was stented with a drug-eluted stent. The postoperative period complicated by the development of acute blood loss associated with bleeding from the upper sections of the gastrointestinal tract, and severe anemia of the combined genesis (posthemorrhagic, renal). This situation required doctors to make non-standard decisions in the choice of antithrombotic therapy. This clinical case illustrates the difficulties in elderly polymorbid patient management in real clinical practice and the controversial issues arising in the prescribing the antithrombotic therapy, especially after bleeding had developed. The supporting guidelines cannot answer all the questions which the daily practice poses to the doctor. In each case, the resumption of antithrombotic therapy and its optimal choice for an elderly polymorbid patient with developed bleeding is the subject of discussion and presented a real challenge for the treating physician.</p></abstract><trans-abstract xml:lang="ru"><p>В последние годы наблюдается очевидная тенденция увеличения в популяции числа пожилых больных. Эти пациенты в большинстве случаев страдают несколькими коморбидными заболеваниями, что значительно утяжеляет прогноз и усложняет тактику ведения. Представлен клинический случай пожилой пациентки, длительное время страдающей сахарным диабетом 2 типа, получающей инсулинотерапию, находящейся на программном гемодиализе из-за терминальной хронической почечной недостаточности, а также имеющей постоянную форму фибрилляции предсердий. Пациентка была госпитализирована в ГКБ №1 им Н.И. Пирогова по поводу острого повторного инфаркта миокарда. Проведено экстренное чрескожное коронарное вмешательство, стентирование инфаркт-зависимой артерии стентом с лекарственным покрытием. Послеоперационный период осложнился развитием острой кровопотери на фоне кровотечения из верхних отделов желудочно-кишечного тракта, тяжелой анемии сочетанного генеза (постгеморрагической, нефрогенной), что потребовало от врачей принятия нестандартных решений по выбору антитромботической терапии. Данный клинический случай иллюстрирует сложности ведения пожилых полиморбидных пациентов в реальной клинической практике, и спорные вопросы, возникающие при назначении им антитромботической терапии, особенно, после развившегося кровотечения. Рекомендательные документы не могут дать ответ на все вопросы, которые ставит перед врачом повседневная практика. В каждом конкретном случае возобновление антитромботической терапии и ее оптимальный выбор для пожилого полиморбидного пациента с развившимся кровотечением является предметом дискуссии, и представляет для лечащего врача настоящий вызов.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>пожилой пациент</kwd><kwd>острый коронарный синдром</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>почечная недостаточность</kwd><kwd>диализ</kwd><kwd>фибрилляция предсердий</kwd><kwd>антитромботическая терапия</kwd><kwd>кровотечение</kwd><kwd>безопасность терапии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>elderly patient</kwd><kwd>acute coronary syndrome</kwd><kwd>percutaneous coronary intervention</kwd><kwd>renal dysfunction</kwd><kwd>hemodialysis</kwd><kwd>atrial fibrillation</kwd><kwd>antithrombotic therapy</kwd><kwd>bleeding</kwd><kwd>safety of treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wan H., Goodkind D., Kowal P. International Population Reports. P95/16-1, An Aging World: 2015. Washington, DC: U.S. Government Publishing Office; 2016.</mixed-citation><mixed-citation xml:lang="en">Wan H., Goodkind D., Kowal P. International Population Reports. P95/16-1, An Aging World: 2015. Washington, DC: U.S. Government Publishing Office; 2016.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lee P.Y., Alexander K.P., Hammill B.G., et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-13.</mixed-citation><mixed-citation xml:lang="en">Lee P.Y., Alexander K.P., Hammill B.G., et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-13.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kandzari D.E., Roe M.T., Chen A..Y, et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005;149:474-81. doi: 10.1016/j.ahj.2004.11.014.</mixed-citation><mixed-citation xml:lang="en">Kandzari D.E., Roe M.T., Chen A..Y, et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005;149:474-81. doi: 10.1016/j.ahj.2004.11.014.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander K.P., Roe M.T., Chen A.Y. et al. Evolution of care for older adults with AMI. J Am Coll Cardiol. 2005;46:1479-97. doi: 10.11909/j.issn.1671-5411.2016.02.012.</mixed-citation><mixed-citation xml:lang="en">Alexander K.P., Roe M.T., Chen A.Y. et al. Evolution of care for older adults with AMI. J Am Coll Cardiol. 2005;46:1479-97. doi: 10.11909/j.issn.1671-5411.2016.02.012.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt M., Jacobsen J.B., Lash T.L., Toft H. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012;344:e356-64. doi: 10.1136/bmj.e356.</mixed-citation><mixed-citation xml:lang="en">Schmidt M., Jacobsen J.B., Lash T.L., Toft H. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012;344:e356-64. doi: 10.1136/bmj.e356.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Suaya J.A., Stason W.B., Ades P.A., et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54(1):25-33. doi: 10.1016/j.jacc.2009.01.078.</mixed-citation><mixed-citation xml:lang="en">Suaya J.A., Stason W.B., Ades P.A., et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54(1):25-33. doi: 10.1016/j.jacc.2009.01.078.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ ehw210.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ ehw210.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393.</mixed-citation><mixed-citation xml:lang="en">Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Roffi M., Patrono C., Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation: Task Force for the Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi: 10.1093/eurheartj/ehv320.</mixed-citation><mixed-citation xml:lang="en">Roffi M., Patrono C., Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation: Task Force for the Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi: 10.1093/eurheartj/ehv320.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12. doi: 10.1016/S01406736(06)68845-4.</mixed-citation><mixed-citation xml:lang="en">Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12. doi: 10.1016/S01406736(06)68845-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes R.D., Rao M., Simon D.N., et al. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med. 2016:;129:592-9. doi: 10.1016/j.amjmed. 2015.12.026.</mixed-citation><mixed-citation xml:lang="en">Lopes R.D., Rao M., Simon D.N., et al. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med. 2016:;129:592-9. doi: 10.1016/j.amjmed. 2015.12.026.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hicks K.A., Stockbridge N.L., Targum S.L., Temple R.J. Bleeding Academic Research Consortium Consensus Report. The Food and Drug Administration Perspective. Circulation. 2011;123:2664-5. doi: 10.1161/CIRCULATIONAHA.111.032433.</mixed-citation><mixed-citation xml:lang="en">Hicks K.A., Stockbridge N.L., Targum S.L., Temple R.J. Bleeding Academic Research Consortium Consensus Report. The Food and Drug Administration Perspective. Circulation. 2011;123:2664-5. doi: 10.1161/CIRCULATIONAHA.111.032433.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Halvorsen S., Storey R.F., Rocca B., et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38(19):1455-62. doi: 10.1093/eurheartj/ehw454.</mixed-citation><mixed-citation xml:lang="en">Halvorsen S., Storey R.F., Rocca B., et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38(19):1455-62. doi: 10.1093/eurheartj/ehw454.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M., Bueno H., Byrne RA., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213-60. doi: 10.1093/eurheartj/ehx419.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M., Bueno H., Byrne RA., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213-60. doi: 10.1093/eurheartj/ehx419.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R., Baber U., Steg P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382:1714-22. doi: 10.1016/S0140-6736(13)61720-1.</mixed-citation><mixed-citation xml:lang="en">Mehran R., Baber U., Steg P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382:1714-22. doi: 10.1016/S0140-6736(13)61720-1.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Steffel J, Verhamme P, Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-93. doi:10.1093/eurheartj/ehy136.</mixed-citation><mixed-citation xml:lang="en">Steffel J, Verhamme P, Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-93. doi:10.1093/eurheartj/ehy136.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mavrakanas Th.A., Samer C.F., Nessim S.J. et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-8. doi: 10.1681/ASN.2016090980.</mixed-citation><mixed-citation xml:lang="en">Mavrakanas Th.A., Samer C.F., Nessim S.J. et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-8. doi: 10.1681/ASN.2016090980.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hao P.P., Zhang M.X., Li R.J., et al. Clopidogrel 150 vs. 75 mg day in patients undergoing percutaneous coronary intervention: a meta-analysis. Journal of Thrombosis and Haemostasis. 2011;9:62737. doi: 10.1111/j.1538-7836.2011.04216.x.</mixed-citation><mixed-citation xml:lang="en">Hao P.P., Zhang M.X., Li R.J., et al. Clopidogrel 150 vs. 75 mg day in patients undergoing percutaneous coronary intervention: a meta-analysis. Journal of Thrombosis and Haemostasis. 2011;9:62737. doi: 10.1111/j.1538-7836.2011.04216.x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
